News
MRK
130.72
+2.93%
3.72
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 2h ago
Health Rounds: New type vaccines may help stop antibiotic resistant bugs
Health Rounds: New type vaccines may help stop antibiotic resistant bugs and better delivery of chemotherapy drugs. Researchers may have come up with a potential solution to the problem of antibiotic resistant bacteria. Merck & Co's Keytruda was approved for kidney cancer treatment in the U.S.
Reuters · 4h ago
Merck (MRK) Q1 2024 Earnings Call Transcript
Merck (MRK 3.04%) Q1 2024 Earnings Call will be held on Thursday, April 25, 2024. Merck's first quarter 2024 conference call will be hosted by Rob Davis, chairman and chief executive officer. The company will also discuss its results for the period ending March 31, 2016. Some of the statements made on the call may be considered forward-looking.
The Motley Fool · 5h ago
MERCK & CO INC: UPDATED INITIAL COMMITMENT TO SUPPLY A TOTAL OF 115 MLN DOSES OF HPV VACCINE THROUGH 2025, AN INCREASE OF APPROXIMATELY 20 MLN DOSES
Reuters · 6h ago
BUZZ-U.S. STOCKS ON THE MOVE-Loar, Regeneron, Intel
U.S. Stocks slumped on Thursday. Dow Jones Industrial Average was down 1.15% and the S&P 500 was down 0.76%. Most megacaps fell after Meta Platforms' quarterly results. Newmont Corp. Was the top percentage gainer on the NYSE and the Nasdaq.
Reuters · 6h ago
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
NASDAQ · 7h ago
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
U.S. Economy grew by a slower-than-expected 1.6% in the first quarter of 2024, missing expectations of 2.5%. Meta Platforms Inc. Saw its worst day since October 2023 as its revenue forecasts were lower than expected. The S&P 500 and the tech-heavy Nasdaq 100 dropped by 1% and 1.2% in Thursday's session. Gold miners in the spotlight following stronger-than expected quarterly results from Newmont Corp.
Benzinga · 7h ago
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
US drug maker Merck & Co Inc reported first-quarter sales of $15.8 billion, up 9% year-over-year. Excluding the impact of foreign exchange, sales increased 24%. Merck's pharmaceutical unit booked $14.01 billion in revenue during the first quarter.
Benzinga · 8h ago
BUZZ-U.S. STOCKS ON THE MOVE-Viking, Alphabet, Dover
U.S. Stocks were sharply lower on Thursday. The Dow Jones Industrial Average was down 1.58% and the S&P 500 and Nasdaq Composite were also down. Meta Platforms dropped 12.7% after dour quarterly results. Newmont Corp was the top percentage gainer on the S.P. 500 and the Nasdaq.
Reuters · 8h ago
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
NASDAQ · 8h ago
S&P 500 Down Over 1%; Merck Increases 2024 Outlook
U.S. Stocks traded lower midway through trading on Thursday. The Dow traded down 1.55% and the Nasdaq Composite fell 1.60%. Merck & Co., Inc. Reported better-than-expected first-quarter financial results. Impinj, Inc. Shares shot up 17% after reporting better- than-expected results. Asian markets closed mostly higher on Thursday but European shares were mostly lower.
Benzinga · 8h ago
Stocks Retreat as Persistent Inflation Dents Fed Rate-Cut Hopes
US stock indexes Thursday closed moderately lower, led by weakness in technology stocks. Large-than-expected downward revision to US Q1 GDP and upward revision to the Q1 core price index fueled fears of stagflation. European stock markets settled mixed; European government bond yields moved higher.
Barchart · 8h ago
MSD (MRK.US)'s best-selling anti-cancer drug Keytruda sales surged 20%, raising full-year EPS expectations
Zhitongcaijing · 9h ago
Dow Movers: IBM, MRK
NASDAQ · 9h ago
MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024
Merck & Co reported earnings per share of $2.07 for the first quarter of 2024. The company reported revenue of $15.78 billion. This was 3.78% better than the analyst estimate for revenue in the same period. Merck and Co also reported results for the fourth quarter of 2015.
Investorplace · 9h ago
Meta Falls 15% On Great Earnings, Tesla Rises 12% On Ugly Earnings – Here Is The Real Reason
The Power of Market Mechanics: Meta Platforms Inc (NASDAQ:META) reported excellent earnings, but the stock fell 15%. Tesla Inc (TSLA) jumped up on heavy AI spending, but Wall Street's positioning was negative. The momo crowd is buying the momo stocks in the early trade. Today's auction of $44B of seven year Treasuries indicates stagflation may be coming.
Benzinga · 9h ago
Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
NASDAQ · 10h ago
MERCK SHARES UP 2.5% AFTER CO RAISES 2024 PROFIT FORECAST
Reuters · 11h ago
Merck & Co Inc reports results for the quarter ended in March - Earnings Summary
Merck & Co Inc reports quarterly adjusted earnings of $2.07 per share for the quarter ended in March. Revenue rose 8.9% to $15.78 billion from the same quarter last year. The company reported quarterly income of $4.76 billion.
Reuters · 11h ago
BUZZ-U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, Valero Energy, Union Pacific
Dow e-minis were down 1.14% in early trading. Chipotle Mexican Grill, Valero Energy, Union Pacific among top U.S. Stocks on the move. Meta Platforms down 15.3% after dour quarterly results. Sign of persistent inflation dampens hopes of Federal Reserve cutting interest rates.
Reuters · 11h ago
More
Webull provides a variety of real-time MRK stock news. You can receive the latest news about Merck & Co through multiple platforms. This information may help you make smarter investment decisions.
About MRK
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.